Private Equity, VC & Investor
BlueYard vs Vitruvian Partners
Structured technology and market comparison · 2026
Direct Feature Comparison
BlueYard · vs · Vitruvian PartnersGermany-based venture capital firm managing technology investment funds.
Private equity firm backing higher-growth companies across Europe and the US.
Analyze all overlapping signals and tech stacks for BlueYard and Vitruvian Partners
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between BlueYard and Vitruvian Partners?
When comparing BlueYard and Vitruvian Partners, both platforms operate within the Private Equity, VC & Investor ecosystem. BlueYard is positioned as Germany-based venture capital firm managing technology investment funds, whereas Vitruvian Partners focuses on Private equity firm backing higher-growth companies across Europe and the US. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to BlueYard and Vitruvian Partners?
When evaluating BlueYard and Vitruvian Partners, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of BlueYard and Vitruvian Partners compare?
BlueYard is headquartered in DE (founded in 2016) with 10–49 employees. Vitruvian Partners is based in GB (founded in 2006) with 50–200 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: BlueYard vs Vitruvian Partners
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
BlueYard
Recent Signals
- ·Tech.eu (European Tech & Deals)Infrastructure
Boxd Raises $2M for AI Coding Agent Cloud Infrastructure
Dutch startup Boxd has raised $2 million in a pre-seed funding round to develop its cloud computing infrastructure designed for developers and AI coding agents. The round was led by BlueYard Capital, with participation from OVNI Capital, Antler, S20, Script Capital, and business angels from General Intuition and other tech companies. Boxd provides hardware-isolated virtual machines that allow AI agents to execute code, run tests, and manage workflows, with features like snapshotting and live-forking in under 100 milliseconds. The company aims to address the infrastructure demands of parallel AI coding agents, offering persistent, secure environments compared to traditional containers. The funding will be used to expand the team and further develop its custom virtualization engine.
- Boxd raised $2 million in a pre-seed funding round.
- The round was led by BlueYard Capital, with participation from OVNI Capital, Antler, S20, and Script Capital.
- Boxd develops cloud infrastructure for developers and AI coding agents.
Vitruvian Partners
Recent Signals
- ·techcrunchFunding
Angle Health raises $600M at $2.7B valuation
Health insurance startup Angle Health announced a $200 million Series C round and a $400 million tender offer, giving the company a $2.7 billion valuation. The round was led by Vitruvian Partners with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. The tender offer permits employees to cash out shares, and the transaction is expected to close later this month. Angle Health, a Winter 2020 Y Combinator alum, helps small businesses manage level-funded health plans, offering a middle ground between fully insured and self-funded options. The company's AI-powered platform integrates with payroll and HR systems, serves over 5,000 businesses, and is reportedly profitable. This funding round is notable as it comes from a non-AI-agent startup founded in 2019.
- Angle Health raised a $200 million Series C round.
- The funding round included a $400 million tender offer.
- The company's valuation is now $2.7 billion.
- ·AdweekAgentic Advertising
DeepIntent launches agentic ad platform Cora for pharma marketing
DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.
- DeepIntent launched Cora, an agentic ad platform for pharma marketing.
- Cora uses AI agents for campaign planning, audience targeting, and execution.
- Cora integrates with VideoAmp for linear TV campaign execution.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners BlueYard and Vitruvian Partners share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks